News | October 06, 2024
Briefs: Aurobindo Pharma and Lupin
USFDA completes PAI of Lupin’s biotech facility in Pune
USFDA completes PAI of Lupin’s biotech facility in Pune
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Total investment incurred for setting up the new R&D Rs 250 crore
The award is for development of Nafithromycin, which is the first ever multi-drug resistant pathogen active respiratory antibiotic for the treatment of Community-Acquired Bacterial Pneumonia
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The USFDA inspection focused on evaluating the facility's adherence to global regulatory requirements and best practices
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Subscribe To Our Newsletter & Stay Updated
